Kaler to - viral gene therapy for menkes disease
Active Awarded Last action
- Contract number
- 75N95024F00003
- Awardee
-
Battelle Memorial Institute UEI F125YU6SWK59
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,018,293
Award facts
- Contract value 49% obligated
-
- $3,109,431.00 Current, with exercised options
- $6,127,724.00 Potential, with all options
- Completion date 69% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Bethesda, MD 20892, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $3,018,293 | |
| Original award | $91,138 |
About this award
Battelle Memorial Institute, a large nonprofit research and development organization headquartered in Columbus, Ohio, was awarded a delivery order on September 30, 2024, by the National Institute on Drug Abuse for viral gene therapy development targeting Menkes disease. The contract, valued at $6.13M with a cost-plus-fixed-fee pricing structure, is scheduled for completion by September 29, 2027, and will be performed in Bethesda, Maryland. This delivery order falls under the larger "Manufacturing and Nonclinical Studies Support for the Development of Therapeutic Biotechnology Products for Neurological-related Disorders" parent contract vehicle, which enables the National Institute on Drug Abuse to access Battelle's specialized capabilities in therapeutic biotechnology research and development. No set-aside designation was applied to this award.
Battelle's selection reflects the contractor's extensive experience in health-related research and scientific advancement, including established relationships with the National Institute of Allergy and Infectious Diseases for pre-clinical evaluation services, vaccine testing support, and animal model development. The contractor's demonstrated expertise in complex research and development across multiple federal agencies, combined with its capacity to manage specialized scientific and technical services, positions it well to execute advanced therapeutic research initiatives. The work supports the National Institute on Drug Abuse's mission to conduct research on drug abuse and addiction, with particular focus on developing innovative genetic therapeutic approaches for neurological conditions like Menkes disease, a rare copper metabolism disorder.
Quick answers
Who was awarded contract 75N95024F00003?
75N95024F00003 was awarded to Battelle Memorial Institute by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2024.
How much is contract 75N95024F00003 worth?
The government has obligated $3,018,293 on 75N95024F00003. Its current value, with exercised options, is $3,109,431. Its potential value, with all options, is $6,127,724.
Is contract 75N95024F00003 an order under another contract?
Yes. 75N95024F00003 is a delivery order under 75N95022D00021, an indefinite delivery contract, on Manufacturing and Nonclinical Studies Support for the Development of Therapeutic Biotechnology Products for Neurological-related Disorders.
Was contract 75N95024F00003 competed?
The extent of competition for 75N95024F00003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award